Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRODIGE 111 – DOMZIGAST
2024-519258-35-00Phase 2Completed
- Sponsor
- Fédération Francophone de Cancérologie Digestive
- Start
- Oct 2025
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of domvanalimab, zimberelimab, irinotecan, fluorouracil and folinic acid in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma and esophageal adenocarcinoma (EAC) (2 arms), sponsored by Fédération Francophone de Cancérologie Digestive. Primary endpoint: Progression-free survival at 6 months. Started Oct 2025; status: completed.
02
Drugs
domvanalimabzimberelimabirinotecanfluorouracilfolinic acid
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinomaesophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on 2024-519258-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519258-35-00.